Election 2014
SENSEX NIFTY

Tablets

Apr 16, 2014 at 10:18 | Source: Moneycontrol.com
Dr Reddys Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA tablets C-IV in the US market on April 15, 2014, following the approval by the USFDA.
Apr 16, 2014 at 09:16 | Source: Moneycontrol.com
Glenmark Generic Inc, USA a subsidiary of Glenmark Generic Limited, has been granted final abbreviated new drug approval (ANDA) from USFDA for Eszopiclone Tablets. Glenmark will commence distribution of the product immediately.
Apr 15, 2014 at 16:30 | Source: PTI
Cadila Healthcare and Zydus Pharmaceuticals today announced in a joint statement that "they have entered into asettlement agreement with Depomed" regarding the patent infringement litigation related to Gralise 300 mg and 600 mg tablets.
Apr 15, 2014 at 10:33 | Source: Moneycontrol.com
Cadila Healthcare and Zudus Pharmaceuticals (USA), Inc have entered into a settlement agreement with Depomed, Inc. to settle their ongoing patent infringement litigation related to Gralise 300mg and 600mg tablets.
Apr 09, 2014 at 16:40 | Source: PTI
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.
Apr 09, 2014 at 14:20 | Source: Moneycontrol.com
Lupin announced today that it has received final approval for its Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Takeda Pharmaceuticals USA, Inc.s (Takeda) Actos Tablets, 15 mg, 30 mg, and 45 mg.
Apr 03, 2014 at 20:40 | Source: PTI
The deal -- that was announced yesterday at Microsoft's BUILD conference in San Francisco -- is expected to intensify competition in the smartphone and tablets space.
Apr 02, 2014 at 15:16 | Source: Moneycontrol.com
Kopran has informed that the United Kingdom, Medicines and Healthcare products Regulatory Agency (UKMHRA) has granted the Certificate of Compliance with principles and guidelines of Good Manufacturing Practice for the Finished Dosage Forms facility located at Savroli, Khalapur, Khopoli manufacturing general capsules arid tablets.
Apr 02, 2014 at 13:34 | Source: Moneycontrol.com
Aurobindo Pharma today received approval from the US Food and Drug Administration for Tramadol Hydrochloride tablets (a painkiller drug).
Mar 27, 2014 at 18:59 | Source: PTI
The company's product is the generic equivalent of Pfizer Inc's Caduet tablets, it added. The Hyderabad-based firm's Amlodipine Besylate and Atorvastatin Calcium tablets are available in bottle counts of 30 and 90, the company said.
Messages on Tablets »

Dr743

Silver Member

3 Followers

Vikram Thermo  

good potential for multobagger... tablet coating manufacturer...and market leader in india...great potential...

6.49 PM Apr 19th

pandyapp

Platinum Member

230 Followers

Sterling Bio  

Sterling Healthcare Pvt. Ltd. - Strengths 1 Wide range of manufacturing capabilities in oral dosage forms- tablets (uncoated, coated), capsules, sachets Sophisticated and automated machines for various 2 manufacturing operations 3 Facility designed to achieve quick turnaround Well qualified and experienced personnel

9.57 PM Apr 18th

pandyapp

Platinum Member

230 Followers

Sterling Bio  

7. Group Overview BusinessDiverse business portfolio Verticals Pharmaceuticals • Contract manufacturing of oral dosage forms. • Manufacturing capabilities in tablets and capsules. • Sophisticated and automated equipments with Automated In-process Quality Assurance (AIQA) •USFDA, TGA, MHRA MCC

9.44 PM Apr 18th

manishnb

Platinum Member

150 Followers

Aurobindo Pharm  

i m eager to know sales for duloxetin cap n repaglinide tablets. Raregem n augur, plz share any data related to it.

5.36 PM Apr 17th

Web Messenger

Platinum Member

208774 Followers

Mobile Tele  

Source:Economic Times - NEW DELHI, KOLKATA: Another irritant threatens India-US business ties that have been on edge of late. India`s proposed new standards for imported electronic gadgets such as tablets and mobiles have irked the US, which has termed them non-tariff barriers in a communication

2.33 PM Apr 17th

Web Messenger

Platinum Member

208774 Followers

Mobile Tele  

Source:BBC - Millions of Android devices remain vulnerable to the Heartbleed bug a week after the flaw was made public. Google announced last week that handsets and tablets running version 4.1.1 of its mobile operating system were at risk. The search giant has since created a fix, but it has yet

1.30 PM Apr 17th

Web Messenger

Platinum Member

208774 Followers

Market Advice  

Source:Economic Times - MUMBAI: Early stage investment firm Kalaari Capital is backing an Indian tablet maker Swipe Telecom that is building a range of low-priced devices. The Pune-based company will receive funding of about Rs 30 crore that will be used to expand sales in the Indian market

12.53 PM Apr 17th

godevents

Platinum Member

95 Followers

Market Strategy - Day Trading  

good morning, now tell what is your view. All birds taken energy tablet. Godevents.....

11.17 AM Apr 17th

Firstpost

Platinum Member

783 Followers

NDTV  

Source:FirstPost - Ranbir Kapoor has been spotted hiding behind tablets among other things to keep his look for Anurag Kashyap`s upcoming film Bombay Velvet under wraps. Until now.Kapoor was recently photographed walking around in a retro waistcoat, and quiff hair NDTV reports. Walking around

2.15 PM Apr 16th

BSE/NSE Announcer

Platinum Member

2329 Followers

Dr Reddys Labs  

Dr. Reddys Laboratories Limited has informed the Exchange regarding a press release April 16, 2014, titled, "Dr. Reddys announces the Launch of Eszopiclone Tablets C-IV."

10.41 AM Apr 16th

News across the web »
Apr 20, 2014 at 06:57 | Source: Calcutta Telegraph News
Apr 19, 2014 at 12:42 | Source: Economic Times
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.